TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31348595

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 11
Study: 28219058

Group type: EXPERIMENTAL
Intervention: Cupping massage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 50
Study: 25679747

Group type: EXPERIMENTAL
Intervention: Study diet (n=10) containing alpha-casozepine and tryptophan, fed for 8 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control diet (n=11), fed for 8 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Study diet (n=10)
Number of subjects: 21
Study: 23769246

Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg + 50 mg tramadol
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg + 100 mg tramadol
Number of subjects: 56
Study: 21208398

Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment programme (oral ivermectin and fenbendazole)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 239
Study: 19798415

Group type: EXPERIMENTAL
Intervention: PfCS102 with AS02A (30 microg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PfCS102 with AS02A (100 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PfCS102 with Montanide ISA 720 (30 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: PfCS102 with Montanide ISA 720 (100 microg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PfCS102 with AS02A (10 microg)
Number of subjects: 36
Study: 16718798

Group type: EXPERIMENTAL
Intervention: 20 mL epinephrine
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 30 mL epinephrine
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 40 mL epinephrine
Number of subjects: 228
Study: 15290120

Group type: EXPERIMENTAL
Intervention: CRT ON
Number of subjects: 10

Group type: COMPARATOR
Intervention: CRT OFF
Number of subjects: 10
Study: 11513170

Group type: EXPERIMENTAL
Intervention: Eradication treatment (lansoprazole 15 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d.)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo treatment (lansoprazole 15 mg b.i.d. and placebo)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 144
Study: 9278202

Group type: EXPERIMENTAL
Intervention: Study group received counseling about their medicines and a pharmaceutical care plan.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group received normal discharge information without additional counseling.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Study group received a domiciliary visit between 7 and 10 days after discharge.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Study group had unintentional changes to medication found during the visit.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group had unintentional changes to medication found during the visit.
Number of subjects: 53
Study: 8305360

Group type: EXPERIMENTAL
Intervention: Double hemibody irradiation (DHBI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: alpha IFN-2b maintenance therapy post-DHBI
Number of subjects: 55
Study: 3524665

Group type: EXPERIMENTAL
Intervention: Oral oestradiol, 2 mg daily plus oestriol, 1 mg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral oestradiol, 2 mg daily
Number of subjects: 14
Study: 30916364

Group type: EXPERIMENTAL
Intervention: 1g/kg of flaxseeds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1g/kg of fenugreek seeds
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of 1g/kg flaxseeds and 1g/kg fenugreek seeds
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (basal diet without any supplementation)
Number of subjects: 120
Study: 30216191

Group type: EXPERIMENTAL
Intervention: Opt-out group (n = 9,556)
Number of subjects: 26556

Group type: EXPERIMENTAL
Intervention: Opt-in group (n = 14,400)
Number of subjects: 26556

Group type: COMPARATOR
Intervention: Control group (n = 2,600)
Number of subjects: 26556

Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 26556

Group type: EXPERIMENTAL
Intervention: HPV self-sampling in non-attenders screened for more than 10 years
Number of subjects: 26556
Study: 26490756

Group type: EXPERIMENTAL
Intervention: Childhood-onset T1DM women
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Adulthood-onset T1DM women
Number of subjects: 214
Study: 23080086

Group type: EXPERIMENTAL
Intervention: Fibrin glue spray applied to the axillary fossa in 40 patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment in 40 patients
Number of subjects: 80
Study: 22613033

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 48
Study: 20044267

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (P‐CRT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 5
Study: 17064888

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 16279891

Group type: EXPERIMENTAL
Intervention: Urgent colonoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 11904128

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10217684

Group type: EXPERIMENTAL
Intervention: Corticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical treatment
Number of subjects: 0
Study: 8747609

Group type: EXPERIMENTAL
Intervention: Relief Band at P6 acupuncture point
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo site
Number of subjects: 9

Group type: COMPARATOR
Intervention: Switching to placebo position from P6
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Switching to P6 position from placebo
Number of subjects: 9
Study: 2095345

Group type: COMPARATOR
Intervention: Furosemide 40 mg alone (F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg and Triamterene 50 mg (F + T)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fixed combination of Furosemide 40 mg and Triamterene 50 mg (FT)
Number of subjects: 12
Study: 351661

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 12

Group type: COMPARATOR
Intervention: false‐EMG biofeedback
Number of subjects: 12
Study: 30452776

Group type: EXPERIMENTAL
Intervention: CSL112 2 g (n = 6)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSL112 6 g (n = 6)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSL112 (both doses)
Number of subjects: 32
Study: 28457194

Group type: EXPERIMENTAL
Intervention: 5 mg ICG administered 3 to 7 hours before imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 10 mg ICG administered 5 to 25 hours before imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5 mg ICG administered up to 3 hours before imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 10 mg ICG administered up to 5 hours before imaging
Number of subjects: 28
Study: 26711904

Group type: EXPERIMENTAL
Intervention: Empower Resilience Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23735727

Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 24
Study: 21815827

Group type: EXPERIMENTAL
Intervention: KCit + Splenda
Number of subjects: 12

Group type: COMPARATOR
Intervention: KCit
Number of subjects: 12
Study: 18482937

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 476

Group type: COMPARATOR
Intervention: Penicillin G benzathine
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 476
Study: 15677701

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 12183309

Group type: EXPERIMENTAL
Intervention: Tailored interventions for urinary tract infections
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tailored interventions for sore throat
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group for urinary tract infections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group for sore throat
Number of subjects: 120
Study: 10213440

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 1
Study: 7753950

Group type: EXPERIMENTAL
Intervention: Implicit memory tasks with varying associative set sizes and word frequencies
Number of subjects: 0
Study: 2191993

Group type: EXPERIMENTAL
Intervention: L-648,051 (inhaled cysteinyl leukotriene antagonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6782930

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 125 mg/10 kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 250 mg/10 kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.4 mg/10 kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.8 mg/10 kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 250 mg/10 kg and Oxycodone 0.8 mg/10 kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 60
Study: 31198138

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC) with initial flow rate of 40 L/min
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine oxygen therapy
Number of subjects: 74
Study: 28348504

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 ml, 8 mg) with bupivacaine (18 ml, 0.5%)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (2 ml normal saline with bupivacaine (18 ml, 0.5%))
Number of subjects: 44
Study: 24642392

Group type: EXPERIMENTAL
Intervention: Biological antioxidant potential (BAP) levels measured at 6 months
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Decreased 6-month BAP level
Number of subjects: 69
Study: 22310838

Group type: EXPERIMENTAL
Intervention: 5-week posturography-assisted vestibular rehabilitation protocol and home-based exercise program (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Awaiting spontaneous compensation (Group B)
Number of subjects: 30
Study: 21502546

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone, consisting of goserelin and bicalutamide for 2 years
Number of subjects: 983
Study: 19467753

Group type: EXPERIMENTAL
Intervention: Crew Resource Management (CRM) training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Classic simulator training (MED)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (CRM and MED)
Number of subjects: 29
Study: 16671435

Group type: EXPERIMENTAL
Intervention: Group A (4 patients with plateau waves)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Group B (4 intracranial hypertensive, hypoperfused patients)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 8

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 8
Study: 15857212

Group type: EXPERIMENTAL
Intervention: D-002 40 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: D-002 100 mg/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12149758

Group type: COMPARATOR
Intervention: Traditional anesthetic (thiopental, pancuronium, 50 microg/kg fentanyl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fast track anesthetic (propofol, cisatracurium, 20 microg/kg fentanyl)
Number of subjects: 80
Study: 10643535

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy with mitozantrone and methotrexate (2M) +/‐ mitomycin‐C (3M) and tamoxifen, used concurrently with radiation
Number of subjects: 184
Study: 7790432

Group type: EXPERIMENTAL
Intervention: New immunodiagnostic method of complement fixation
Number of subjects: 0
Study: 2112120

Group type: EXPERIMENTAL
Intervention: 8 Gy in 1 fraction
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 10 Gy in 5 fractions
Number of subjects: 37
Study: 373632

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trimipramine maleate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31623638

Group type: EXPERIMENTAL
Intervention: Pilates training (36 sessions)
Number of subjects: 54
Study: 27866873

Group type: EXPERIMENTAL
Intervention: Open-label tenofovir (300 mg daily) for 1 year
Number of subjects: 1315
Study: 26556601

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physical modality (SIT)
Number of subjects: 41
Study: 23665299

Group type: EXPERIMENTAL
Intervention: Education on reading food labels to choose low sodium products (single session)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual diet (Control group)
Number of subjects: 78
Study: 21917824

Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: SC placebo
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg) reintroduced after placebo
Number of subjects: 167
Study: 19444379

Group type: EXPERIMENTAL
Intervention: Beverage containing 200 mg calcium and 5 microg vitamin D daily for 30 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Beverage containing 200 mg calcium daily for 30 days
Number of subjects: 64
Study: 17535285

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and aluminium lactate-containing toothpaste (test group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Minus active control toothpaste (control group)
Number of subjects: 59
Study: 15582922

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 20
Study: 11169032

Group type: EXPERIMENTAL
Intervention: High-flux ultrafiltrates (UFs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-flux ultrafiltrates (UFs)
Number of subjects: 0
Study: 9504950

Group type: EXPERIMENTAL
Intervention: Total osteocalcin (tOC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Undercarboxylated osteocalcin (ucOC)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Subjects with hip fracture
Number of subjects: 257
Study: 8048341

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 54
Study: 2737797

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 6
Study: 31335305

Group type: EXPERIMENTAL
Intervention: Physical Activity for Lent (PAL) program
Number of subjects: 128
Study: 30477276

Group type: EXPERIMENTAL
Intervention: Lowest serum 25(OH)D quartile (4.7–17.5 ng/mL)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Higher serum 25(OH)D quartile
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Second serum 25(OH)D quartile
Number of subjects: 271
Study: 27863599

Group type: EXPERIMENTAL
Intervention: Muscle relaxation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Support group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 25103953

Group type: EXPERIMENTAL
Intervention: Postoperative glycemic dysregulation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgically revised patients
Number of subjects: 75
Study: 22197127

Group type: EXPERIMENTAL
Intervention: degarelix-ML group
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 85
Study: 20525274

Group type: EXPERIMENTAL
Intervention: Motavizumab followed by Palivizumab (M/P)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Palivizumab followed by Motavizumab (P/M)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Motavizumab only (control)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 260
Study: 17906021

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 16141775

Group type: EXPERIMENTAL
Intervention: HEARTFELT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated historical control)
Number of subjects: 0
Study: 12441212

Group type: EXPERIMENTAL
Intervention: Ambient temperature
Number of subjects: 333

Group type: COMPARATOR
Intervention: Barometric pressure
Number of subjects: 333
Study: 9935007

Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 146

Group type: COMPARATOR
Intervention: No antiarrhythmic medication (ICD-only group)
Number of subjects: 146
Study: 7591508

Group type: EXPERIMENTAL
Intervention: High hypnotizability (10-12 SHSSC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Low hypnotizability (0-4 SHSSC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High hypnotizability (10-12 SHSSC) with angry emotional valence presented to the right hemisphere (LVF)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subjects with higher absorption and sustained attention
Number of subjects: 33
Study: 2267970

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg) administered monthly for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg) administered monthly for 8 and 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg) administered monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 0
Study: 6104874

Group type: EXPERIMENTAL
Intervention: Fixed betablocker diuretic combination (Torrat, Boehringer Mannheim GmbH)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Single components (metipranolol and butizide)
Number of subjects: 66
Study: 31783279

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: Major bleeding events
Number of subjects: 13885
Study: 31798894

Group type: EXPERIMENTAL
Intervention: Boot Camp intervention (diabetes education and medication management via initial clinic and weekly virtual visits for 90 days)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Boot Camp intervention
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual diabetes care management (control group)
Number of subjects: 366
Study: 29989320

Group type: EXPERIMENTAL
Intervention: Metaphorical restructuring
Number of subjects: 88

Group type: COMPARATOR
Intervention: Literal restructuring
Number of subjects: 88

Group type: COMPARATOR
Intervention: No restructuring
Number of subjects: 88
Study: 27590218

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg per day (reduced to 30 mg if certain factors present)
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin-warfarin
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study: 24604308

Group type: EXPERIMENTAL
Intervention: Doxycycline 50 mg daily for 24 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22313516

Group type: EXPERIMENTAL
Intervention: Amantadine 50 or 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20841613

Group type: COMPARATOR
Intervention: 10 units of lispro
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30 units of lispro
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50 units of lispro
Number of subjects: 7
Study: 17602978

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study: 15617963

Group type: EXPERIMENTAL
Intervention: Bilateral symmetrical stair‐case technique
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bilateral method using two asymmetrical flaps
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Unilateral flap
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bernard‐Freeman‐Fries technique
Number of subjects: 48
Study: 12374520

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate, 1500 mg once a day
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 202
Study: 10815855

Group type: EXPERIMENTAL
Intervention: Excimer laser‐generated 308‐nm UV‐B radiation (1 treatment at 8 and 16 MED multiples)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Excimer laser‐generated 308‐nm UV‐B radiation (low and medium fluences)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Excimer laser‐generated 308‐nm UV‐B radiation (high fluences)
Number of subjects: 13
Study: 8984537

Group type: EXPERIMENTAL
Intervention: Imipenem + vancomycin (arm A)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Imipenem + teicoplanin (arm B)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Sequential empiric therapy including amikacin and amphotericin B
Number of subjects: 126

Group type: COMPARATOR
Intervention: Overall group
Number of subjects: 126
Study: 1455126

Group type: EXPERIMENTAL
Intervention: Morning Tendency group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-Morning Tendency group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 3881032

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 1% levobunolol
Number of subjects: 162

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 162

Group type: COMPARATOR
Intervention: levobunolol vs timolol
Number of subjects: 162
Study: 30299241

Group type: EXPERIMENTAL
Intervention: TCZ+MTX
Number of subjects: 165

Group type: COMPARATOR
Intervention: TCZ+PBO
Number of subjects: 165